HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Intimate beauty

This article was originally published in The Rose Sheet

Executive Summary

VP and CEO Michael Newman to leave Intimate Brands at year-end, IBI announces at third quarter earnings meeting Nov. 14. Newman, who has been with the firm since June, is resigning to focus on personal interests. An external search for a successor is underway. Bath & Body Works opened 110 stores in the period and will open 20 more in the fourth quarter. BBW recorded 5% gain in comparable store sales and 27% increase in operating income in the third quarter. IBI net sales were $925 mil., a 14% increase over the year-ago period, and net income jumped 12% to $43 mil

You may also be interested in...



Intimate Brands

Tracey Thomas Travis to VP, finance and CFO from Rexam Beverage Can Americas, where she was CFO. Prior to joining Rexam in 1999, Travis worked at Pepsi-Cola for 10 years in various financial roles, including market unit general manager in Michigan. Effective immediately, Travis succeeds Michael Newman, who left the company in late 2000 to pursue personal interests (1"The Rose Sheet" Nov. 20, 2000, In Brief)

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS008675

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel